As reported previously, Park et al. (38) suggested that the combination of oxaliplatin and capecitabine was involved in the immune regulation of the liver metastatic CRC microenvironment via the cGAS-STING pathway. This evidence concerns the gene CGAS and colorectal carcinoma.